Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04461015 · ClinicalTrials.gov registry record · Phase 3

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

A Phase 3 study of Healthy, sponsored by Adrian Vella.

Completed
Registry status
Phase 3
Development phase
12
Enrollment target
1
Study location

NCT04461015: Completed Phase 3 study of Healthy, sponsored by Adrian Vella.

NCT04461015 is a Phase 3 study of Healthy that has completed, run by Adrian Vella. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04461015, a Phase 3 study of Healthy, has completed, sponsored by Adrian Vella.

COMPLETED
Registry status
Phase 3
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to help understand the relative importance of changes in insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to regulate metabolism and the body's ability to make glucose.

Primary Outcome

is calculated by tracer-based measurement and expressed per kg lean body mass

Conditions Studied

Interventions

  • DRUG 0.4mU Insulin followed by withdrawal period followed by 0.8mU study
  • DRUG 0.8mU Insulin followed by withdrawal period followed by 0.4mU study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2020-10-14
Est. Completion 2022-01-06
Phase Phase 3
Adrian Vella

9 total trials

What the finished NCT04461015 record still lists

NCT04461015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which 0.4mU Insulin followed by withdrawal period followed by 0.8mU study is the first listed.

NCT04461015 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT04461015 about?

NCT04461015 is a clinical study titled "The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans". The purpose of this research is to help understand the relative importance of changes in insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to regulate metabolism and the body's ability to make glucose.

What is the current status of trial NCT04461015?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2020-10-14. Estimated completion is 2022-01-06.

What conditions does trial NCT04461015 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT04461015?

The interventions under investigation include: 0.4mU Insulin followed by withdrawal period followed by 0.8mU study (DRUG), 0.8mU Insulin followed by withdrawal period followed by 0.4mU study (DRUG).

Who is sponsoring clinical trial NCT04461015?

This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04461015 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04461015's enrollment target sits among peer trials

12 996th of 1090 higher than 61 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04461015, the US trial registry maintained by the National Library of Medicine. NCT04461015 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.